Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intrathecal baclofen

G A Ochs1

  • 1Department of Neurology, University of Würzburg, Germany.

Bailliere'S Clinical Neurology
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Intrathecal baclofen, a GABA-B agonist, effectively treats severe spinal spasticity and improves patient mobility, function, and bladder control. This implantable drug delivery method is safe and offers superior outcomes compared to oral medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Remyelination in demyelinating disease.

Bailliere's clinical neurology·1999
Same journal

Other immunomodulatory therapies in multiple sclerosis.

Bailliere's clinical neurology·1999
Same journal

Copolymer-1.

Bailliere's clinical neurology·1999
Same journal

Interferon beta 1a.

Bailliere's clinical neurology·1999
Same journal

Treatment of multiple sclerosis with interferon beta 1b.

Bailliere's clinical neurology·1999
Same journal

The cause and management of bladder, sexual and bowel symptoms in multiple sclerosis.

Bailliere's clinical neurology·1999

Area of Science:

  • Neurology
  • Neurosurgery
  • Pharmacology

Background:

  • Intrathecal baclofen (ITB) is increasingly utilized for managing severe spasticity.
  • Over 1000 patients globally have received ITB therapy since its 1984 introduction.
  • ITB involves implantable drug administration devices for continuous medication delivery.

Purpose of the Study:

  • To evaluate the efficacy and safety of intrathecal baclofen for severe spasticity.
  • To present clinical data from 48 patients and multicenter trial experience.
  • To provide a literature overview on ITB therapy.

Main Methods:

  • Intrathecal administration of the GABA-B agonist baclofen.
  • Utilized implantable drug administration devices for continuous infusion.

Related Experiment Videos

  • Compiled clinical data from 48 patients and European multicenter trial results.

    • Main Results:

    • ITB is a powerful treatment for spasticity from spinal lesions, improving mobility, function, and pain.
    • Significant improvements observed in bladder function, including increased volume and reduced residual volume.
    • While less pronounced in supraspinal lesions, ITB shows superior clinical effects over oral treatments.

    Conclusions:

    • Intrathecal baclofen is generally accepted as a safe and effective treatment for spinal spasticity.
    • The method has overcome initial technical challenges, ensuring procedural safety.
    • ITB therapy offers substantial patient benefits, including enhanced function and pain relief.